Literature DB >> 19397415

Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects.

Katarina Radosević1, Ariane Rodriguez, Angelique Lemckert, Jaap Goudsmit.   

Abstract

Classical vaccination approaches, based on a single vaccine administered in a homologous prime-boost schedule and optimized to induce primarily neutralizing antibodies, are unlikely to be sufficiently efficacious to prevent TB, malaria or HIV infections. Novel vaccines, capable of inducing a more powerful immune response, in particular T-cell immunity, are desperately needed. Combining different vaccine modalities that are able to complement each other and induce broad and sustainable immunity is a promising approach. This review provides an overview of heterologous prime-boost vaccination modalities currently in development for the 'big three' poverty-related diseases and emphasizes the need for innovative vaccination approaches.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19397415     DOI: 10.1586/erv.09.14

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  27 in total

1.  Sequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses.

Authors:  Rekha Singh; Alan L Rothman; James Potts; Farshad Guirakhoo; Francis A Ennis; Sharone Green
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

Review 2.  Vaccines: the fourth century.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2009-09-30

3.  Simultaneous priming with DNA encoding Sm-p80 and boosting with Sm-p80 protein confers protection against challenge infection with Schistosoma mansoni in mice.

Authors:  Loc Le; Weidong Zhang; Souvik Karmakar; Gul Ahmad; Workineh Torben; Afzal A Siddiqui
Journal:  Parasitol Res       Date:  2014-01-23       Impact factor: 2.289

4.  A peptide-based Plasmodium falciparum circumsporozoite assay to test for serum antibody responses to pre-erythrocyte malaria vaccines.

Authors:  Stefan Kostense; Bregje Mommaas; Jenny Hendriks; Mariëlle Verhoeven; Mariska Ter Haak; Felicia Tirion; Edison Wiesken; Maria Grazia Pau; Katarina Radosevic; Jaap Goudsmit
Journal:  Clin Vaccine Immunol       Date:  2011-03-16

5.  Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against Trypanosoma cruzi infection.

Authors:  Eiji Takayama; Takeshi Ono; Elena Carnero; Saori Umemoto; Yoko Yamaguchi; Atsuhiro Kanayama; Takemi Oguma; Yasuhiro Takashima; Takushi Tadakuma; Adolfo García-Sastre; Yasushi Miyahira
Journal:  Int J Parasitol       Date:  2010-07-08       Impact factor: 3.981

6.  Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.

Authors:  Kristopher Kolibab; Amy Yang; Steven C Derrick; Thomas A Waldmann; Liyanage P Perera; Sheldon L Morris
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

7.  Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi.

Authors:  Paula Ordonhez Rigato; Bruna C de Alencar; José Ronnie C de Vasconcelos; Mariana R Dominguez; Adriano F Araújo; Alexandre V Machado; Ricardo T Gazzinelli; Oscar Bruna-Romero; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2011-02-28       Impact factor: 3.441

8.  The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.

Authors:  Katarina Radosevic; Ariane Rodriguez; Angelique A C Lemckert; Marjolein van der Meer; Gert Gillissen; Carolien Warnar; Rie von Eyben; Maria Grazia Pau; Jaap Goudsmit
Journal:  Clin Vaccine Immunol       Date:  2010-09-08

9.  The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.

Authors:  Brian Abel; Michele Tameris; Nazma Mansoor; Sebastian Gelderbloem; Jane Hughes; Deborah Abrahams; Lebohang Makhethe; Mzwandile Erasmus; Marwou de Kock; Linda van der Merwe; Anthony Hawkridge; Ashley Veldsman; Mark Hatherill; Giulia Schirru; Maria Grazia Pau; Jenny Hendriks; Gerrit Jan Weverling; Jaap Goudsmit; Donata Sizemore; J Bruce McClain; Margaret Goetz; Jacqueline Gearhart; Hassan Mahomed; Gregory D Hussey; Jerald C Sadoff; Willem A Hanekom
Journal:  Am J Respir Crit Care Med       Date:  2010-02-18       Impact factor: 21.405

10.  DNA vaccination partially protects against African swine fever virus lethal challenge in the absence of antibodies.

Authors:  Jordi M Argilaguet; Eva Pérez-Martín; Miquel Nofrarías; Carmina Gallardo; Francesc Accensi; Anna Lacasta; Mercedes Mora; Maria Ballester; Ivan Galindo-Cardiel; Sergio López-Soria; José M Escribano; Pedro A Reche; Fernando Rodríguez
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.